A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer
Japanese Journal of Clinical Oncology · 13.03.2026 · 56 (3) · 274-281
DOI: 10.1093/jjco/hyaf192 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 04.12.2025. Verfasst von Yoshiaki Nagatani und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: Nivolumab, Salivary Gland Neoplasms, Neoplasm Recurrence, Local, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Scientific Research C, Ministry of Education, Culture, Sports, Science and Technology, Japan.
Abstract (Originalsprache)
Background
Salivary gland cancer (SGC) is rare and has various histological types. This rarity and heterogeneity have hindered elucidation of the therapeutic contribution of systemic therapy, including immune checkpoint inhibitors, to recurrent or metastatic SGC (RM-SGC). The purpose of this trial was to investigate the efficacy and safety of nivolumab for platinum-refractory RM-SGC.
Methods
This phase II trial for platinum-refractory RM-SGC was conducted at nine centers. Nivolumab 240 mg was administered intravenously every 2 weeks. The primary endpoint was the objective response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.
Results
Twenty-four patients were enrolled between March 2018 and January 2022. The main histological types were salivary duct carcinoma (n = 10), adenoid cystic carcinoma (n = 6), and adenocarcinoma not otherwise specified (n = 5). The ORR was 8.3% (2/24, 80% CI, 2.2–20.6), with two partial responses in patients with salivary duct carcinoma. The DCR was 29.2% (7/24), while all of the other 17 patients (70.8%) showed progressive disease on first disease evaluation at 12 weeks. With a median follow-up of 21.2 months, median PFS and OS were 3.0 months (95% CI, 2.8–3.2) and 25.0 months (95% CI, 10.9–39.1), respectively. There were no new safety concerns with nivolumab monotherapy.
Conclusions
This phase II trial of nivolumab for patients with platinum-refractory RM-SGC did not meet its primary endpoint of ORR. Although nivolumab may be worth further development in salivary duct carcinoma, these results may raise concerns over nivolumab monotherapy for RM-SGC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
- Kobe University Hospital Cancer Center, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
- Department of Head and Neck Oncology, Miyagi Cancer Center, 47-1 Nodayama, Medeshimashiode, Natori, Miyagi 981-1293, Japan.
- Department of Head and Neck Oncology Division, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan.
- Department of Head and Neck Surgery, Miyagi Cancer Center, 47-1 Nodayama, Medeshimashiode, Natori, Miyagi 981-1293, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki 569-8686, Japan.
ORCID-Profile: Yoshiaki Nagatani, Naomi Kiyota, Hironaga Satake, Hirokazu Uemura, Yohei Funakoshi
Förderung
- Scientific Research C
- Ministry of Education, Culture, Sports, Science and Technology, Japan
Zitieren
APA
Nagatani, Y., Kiyota, N., Yamazaki, T., Asada, Y., Higashino, M., Satake, H., Boku, S., Nishimura, A., Uemura, H., Ota, I., Yane, K., Tanaka, K., Onoe, T., Hirayama, Y., Tsujikawa, T., Fujiwara, H., Shimoda, H., Nibu, K. I., Imamura, Y., …, & Minami, H. (2026). A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer. Japanese Journal of Clinical Oncology, 56(3), 274-281. https://doi.org/10.1093/jjco/hyaf192
Vancouver
Nagatani Y, Kiyota N, Yamazaki T, Asada Y, Higashino M, Satake H, et al. A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer. Japanese Journal of Clinical Oncology. 2026;56(3):274-281. doi:10.1093/jjco/hyaf192
BibTeX
@article{Nagatani2026,
author = {Nagatani, Yoshiaki and Kiyota, Naomi and Yamazaki, Tomoko and Asada, Yukinori and Higashino, Masaaki and Satake, Hironaga and Boku, Shogen and Nishimura, Ari and Uemura, Hirokazu and Ota, Ichiro and Yane, Katsunari and Tanaka, Kaoru and Onoe, Takuma and Hirayama, Yuji and Tsujikawa, Takahiro and Fujiwara, Hajime and Shimoda, Hikari and Nibu, Ken-Ichi and Imamura, Yoshinori and Kimbara, Shiro and Koyama, Taiji and Funakoshi, Yohei and Minami, Hironobu},
title = {A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
volume = {56},
number = {3},
pages = {274--281},
doi = {10.1093/jjco/hyaf192}
}
EUVIMED